Grants and Contracts Details
HUMAN CLINICAL TRIAL - CONFIDENTIAL To assess the safety and tolerability of the daily oral administration of nilotinib (150-300mg once daily) in moderate/advanced and early/de novo PD participants.
|Effective start/end date||11/7/17 → 9/17/19|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.